| Company Name | AbbVie Biopharmaceuticals GmbH Taiwan Branch |
|---|---|
| Protocol Number | P16-326 |
| Title of Study | A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST) |
| Primary Objective | The objectives of this prospective observational study are to collect the local data of clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) in AS patients after the initiation of adalimumab therapy from routine clinical practices in Taiwan. |
| Number of Sites | 12 |
| Period of Study | From：Mar 2018 to：Dec 2020 |
| Number of Patients | 140人 |
| IRB Approval Date | CGMH: 12 Feb 2018 BTCMF: 05 Feb 2018 NTUH: 16Jan2018 TSGH: 12 Jan 2018 |
| Publication Plan / Date | To be determined |
